Results 121 to 130 of about 17,302 (216)

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1318-1326, November 2026.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka   +6 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner   +12 more
wiley   +1 more source

TP53 mutations and Azacitidine treatment: To be or not to be related?

open access: yes, 2014
TP53 mutations and Azacitidine ...
CUNEO, Antonio, RIGOLIN, Gian Matteo
core  

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines

open access: yes
Azacitidine, a DNA methylation inhibitor, is employed for the treatment of acute myeloid leukemia (AML). However, drug resistance remains a major challenge for effective azacitidine chemotherapy, though several studies have attempted to uncover the ...
Heewon Park, Satoru Miyano
core   +1 more source

A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. [PDF]

open access: yesBlood Adv
Amaya ML   +16 more
europepmc   +1 more source

Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP. [PDF]

open access: yesBlood Cancer Discov
Luo Q   +14 more
europepmc   +1 more source

Treatment of Acute Myeloid Leukemia in the Elderly. [PDF]

open access: yesHematol Rep
Vadnagara H   +5 more
europepmc   +1 more source

Efficacy and safety of risk-stratified chemotherapy with azacitidine for children with myeloid leukaemia with Down syndrome: protocol for a multicentre phase II trial (JCCG AML-D24). [PDF]

open access: yesBMJ Open
Nakashima K   +23 more
europepmc   +1 more source

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

open access: yes
International audienceVenetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do ...
Laribi, Kamel   +27 more
core   +1 more source

Home - About - Disclaimer - Privacy